Vanda Pharmaceuticals
VNDA
101 hedge funds and large institutions have $428M invested in Vanda Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 16 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
8% less funds holding
Funds holding: 110 → 101 (-9)
23% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $13.7M
31% less capital invested
Capital invested by funds: $622M → $428M (-$195M)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$14.2M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$11.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.88M |
| 4 |
Millennium Management
New York
|
+$4.71M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.36M |
| 2 |
CCM
Cupps Capital Management
Chicago,
Illinois
|
-$2.01M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.67M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.55M |
| 5 |
SCA
Signpost Capital Advisors
New York
|
-$1.5M |
VNDA Hedge Fund Activity: Q3 2014 in Review
101 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2014, worth a combined $428M — down 31% from $622M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VNDA and 7 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 38 added.
The largest buyer was Deerfield Management, adding an estimated $14.2M. The largest seller was OrbiMed, exiting entirely with an estimated $7.36M sold.
- 101 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2014, down from 110 in Q2 2014.
- Funds reported $428M of Vanda Pharmaceuticals stock for Q3 2014, down 31% quarter-over-quarter.
- 7 funds opened new Vanda Pharmaceuticals positions in Q3 2014 and 16 closed out, a net change of -9 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2014 was Deerfield Management, an estimated $14.2M added.
- The largest Vanda Pharmaceuticals seller in Q3 2014 was OrbiMed, an estimated $7.36M sold.
Based on aggregated 13F filings for Q3 2014.